Mirum Pharmaceuticals (MIRM) Net Cash Flow Growth (3y) (2022 - 2026)
Mirum Pharmaceuticals (MIRM) Net Cash Flow Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.39 Bn | 467.60 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 122.08 Bn | 114.83 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.97 Bn | 50.78 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn | 32.17% |
| 10 | Mirum Pharmaceuticals | 6.70 Bn | 6.31 Bn | 131.08 Mn | 11.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.90% |
| Dec 31, 2025 | 59.40% |
| Sep 30, 2025 | 68.07% |
| Jun 30, 2025 | 16.03% |
| Mar 31, 2025 | -40.71% |
| Dec 31, 2024 | -77.05% |
| Sep 30, 2024 | 34.40% |
| Jun 30, 2024 | -284.92% |
| Mar 31, 2024 | 32.37% |
| Dec 31, 2023 | -29.67% |
| Sep 30, 2023 | 29.65% |
| Jun 30, 2023 | 137.77% |
| Mar 31, 2023 | -29.30% |
| Dec 31, 2022 | 25.34% |
| Sep 30, 2022 | -21.02% |
| Jun 30, 2022 | 47.07% |
| Mar 31, 2022 | 100.39% |